Physician profile
Don Smith
NPI 1528155850
$4,500.83
in general payments reported to CMS, 2019-2025
23 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $785 · 2021: $270 · 2022: $297 · 2023: $333 · 2024: $1,594 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $859.89 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $473.98 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $451.71 | 2019-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.59 | 2020-2025 | Caplyta |
| Abbvie INC. | $329.85 | 2021-2024 | Vraylar |
| Tris Pharma INC | $319.18 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $286.62 | 2019-2024 | Trintellix |
| Allergan, INC. | $254.67 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $164.72 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $139.91 | 2022-2024 | Auvelity |
| Corium, LLC | $138.18 | 2023-2024 | Azstarys |
| Alkermes, INC. | $124.63 | 2019-2023 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $100.24 | 2019-2021 | |
| Shire North American Group INC | $92.17 | 2019 | |
| Vanda Pharmaceuticals INC. | $87.07 | 2019-2025 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $44.93 | 2024 | |
| Janssen Pharmaceuticals, INC | $39.36 | 2023-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $37.50 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $36.21 | 2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $27.74 | 2020 | |
| Sage Therapeutics, LLC | $25.68 | 2024 | |
| Owp Pharmaceuticals, INC. | $19.12 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.88 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.